Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of Intravaginal Tamoxifen (DARE-VVA1): Randomized, Double-blind, Placebo-controlled Study of Safety, Pharmacokinetics and Pharmacodynamics in Postmenopausal Participants With Moderate to Sever Vulvar and Vaginal Atrophy

Trial Profile

Phase 1/2 Study of Intravaginal Tamoxifen (DARE-VVA1): Randomized, Double-blind, Placebo-controlled Study of Safety, Pharmacokinetics and Pharmacodynamics in Postmenopausal Participants With Moderate to Sever Vulvar and Vaginal Atrophy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tamoxifen (Primary)
  • Indications Atrophic vaginitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Dare Bioscience

Most Recent Events

  • 21 Sep 2023 Results assessing safety, systemic pharmacokinetics and preliminary efficacy of a vaginal tamoxifen capsule among postmenopausal women with moderate-to-severe vulvovaginal atrophy published in the Climacteric
  • 20 Sep 2023 According to a Dare Bioscience media release, data from this study will be presented at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American Menopause Society, or NAMS) taking place September 27-30, 2023 at the Marriott Downtown in Philadelphia, PA.
  • 17 Jul 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top